Navigation Links
Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
Date:8/7/2008

Patient Recruitment Continues for Clinical Trial of ALXN6000 in Cancer

CHESHIRE, Conn., Aug. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Patent and Trademark Office has issued Patent Number 7,408,041 titled, "Polypeptides and Antibodies Derived from Chronic Lymphocytic Leukemia Cells and Uses Thereof." The patent is assigned to Alexion and includes claims that encompass the composition-of-matter of Alexion's anti-CD200 humanized monoclonal antibody, which is known by its working name, ALXN6000.

"Alexion continues to be focused on developing first-in-class therapeutics for patients who have severe and life-threatening medical conditions, and few, if any, treatment options," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "We are committed to fully investigate the therapeutic potential of ALXN6000 as a drug therapy for patients with B-cell chronic lymphocytic leukemia and other hematologic and solid-tumor cancers."

The U.S. Food and Drug Administration ("FDA") recently authorized Alexion's Investigational New Drug application ("IND") for a clinical trial of ALXN6000 as a treatment for patients with refractory or relapsing B-cell Chronic Lymphocytic Leukemia ("CLL"). As previously announced, dosing in an open-label Phase I/II trial has commenced. Recruitment and dosing of patients in the trial is expected to continue through 2009. More information is available at the http://www.clinicaltrials.gov website maintained by the U.S. National Institutes of Health.

About ALXN6000

The CD200 molecule is overexpressed in certain tumor cells and may inhibit the body's immune response to that
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. GeoVax Secures $10 Million Financing Commitment
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
6. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
7. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
8. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
11. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Sage Analytics ( www.sageanalytics.com ), the developers ... measurement systems, announced its sponsorship of the California Cannabis ... limited number of tickets are available for groups or ... cause while enjoying an open bar, buffet dinner and ... Francisco Bay at sunset. With the legislative ...
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
(Date:8/3/2015)... Biosensors International Group, Ltd. ("Biosensors" or ... B20), a developer, manufacturer and marketer of innovative ... first fiscal quarter ended 30 June 2015 ("Q1 ... Developments: , Biosensors continued to ... driven by lower operating expenses and operational improvement. ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... industry-defining contract lifecycle management solution, as well as announced the date of its ... speed and ease of contract management tasks as well as enhancements to the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... disorders (TD) was first described about 40 years ago. ... (PA) and Thyroiditis on the basis of gastric and ... on this frequently overlooked association. , A research article ... World Journal of Gastroenterology investigates the overlooked association. A ...
... with the annual,HIMSS healthcare IT conference, RemoteScan Corporation,( ... new pricing of,its popular RemoteScan(R) software. RemoteScan makes ... software to scan directly into any,medical document management ... or Windows Terminal Services servers. In addition to ...
... week Citi-Mobile,launched a new mobile billboard campaign to ... generously donated their mobile,billboards to the National Autism ... family assistance, and cutting-edge,research., The mobile billboards ... the cities of Glendale and Burbank. Kevin Bartanian, ...
... heart disease, study finds , , WEDNESDAY, Feb. 27 (HealthDay News) ... and adolescents with normal blood sugar levels had elevated markers ... for both type 2 diabetes and cardiovascular disease. , Researchers ... 10 to 18. Of those, 17 were lean and 21 ...
... WASHINGTON, Feb. 27 Following is the daily,Black History ... WEDNESDAY, FEBRUARY 27: INCOME & HEALTH INSURANCE, ... Month. The progress,of any segment of the U.S. population ... financial health. Recent figures show that the annual median ...
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer ... that,it plans to release fourth quarter and full year ... 2008 before the market opens., The Company will ... ET to,discuss results. Listeners may access the call by ...
Cached Medicine News:Health News:Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease? 2Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2Health News:Overweight Hispanic Kids Show Early Markers for Diabetes 2Health News:American Oriental Bioengineering to Report Fourth Quarter and Full Year 2007 Financial Results 2